- Chronic/Congestive Heart Failure
- Hypertension
- Obesity
- Type II Diabetes
- Others
Cardiometabolic Disease Market size was valued around USD 120.4 Bn in 2022 and is poised to grow at a significant CAGR of 3.8% over 2023-2029. Some of the key factors influencing the market growth include growing demand for a healthy lifestyle as it a crucial for maintenance. Due to rapidly changing lifestyle, food habits and genetic predisposition, rising in the incidence of various diseases such as diabetes, high cholesterol, cardiovascular disease, hypertension and others. Additionally, increasing awareness and government initiatives on public healthcare will fuel the market growth. Huge demand for plants based nutritional products and treatment requires a combination of nourishing, behavioral, and drug treatments, wherein drugs act as an assistant to behavioral therapies. Additionally, increase in acceptance of dietary food supplements and technological advancement in biotechnology for launching new products boosting the market growth. However, lack of awareness among the aged population and lack of standard norms and regulations regarding the medical facilities are some of the factor hinder the market growth. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global cardiometabolic disease market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global cardiometabolic disease market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Study Period
2024-2030Base Year
2023CAGR
3.8%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Cardiometabolic disease slowly leads to numerous various disease such as BP, chronic heart failure central adiposity, and dyslipidemia that increase the risks of patients to suffer from other life threating diseases. Moreover, rising awareness regarding the proper healthcare management fueling the market growth. In addition, high growth in emerging economies provides huge growth opportunity for the market. Increasing number of patients accepting medications and therapeutics due to the spread of digital modes of drug delivery systems will boost the market growth, Further, rising funds and increasing emphasis on the medical sector will fuel the market growth.
By Type
By Treatment
By Distribution Channel
By Geography
The CAGR of the cardiometabolic disease market is 3.8% over the forecast period (2023 - 2029)
AstraZeneca plc, Cardax, Inc., Dicerna Pharmaceuticals, Inc., Eli Lilly and Company
The Asia Pacific is the fastest-growing region for the cardiometabolic disease market